These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 34781659)

  • 1. Expert Opinion on P2Y12 Inhibitors Use in Management of Acute Coronary Syndromes: Focus on Ticagrelor.
    Sathyamurthy I; Hiremath MS; Sawhney JP; Chandra S; Mishra H; Ponde CK; Ray S; Hardas S; Sathe S; Rath PC; R B; Navasundi GB; Magarkar V; Makhale CN; Banerjee S; Vaidyanathan PR; Sen AK; Bp P; C SO
    J Assoc Physicians India; 2021 Oct; 69(10):11-12. PubMed ID: 34781659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review.
    Kamran H; Jneid H; Kayani WT; Virani SS; Levine GN; Nambi V; Khalid U
    JAMA; 2021 Apr; 325(15):1545-1555. PubMed ID: 33877270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency and Reasons of Dual Antiplatelet Therapy Discontinuation and Switching of P2Y12 Inhibitors in Patients with Acute Coronary Syndrome Treated with Stent Implantation.
    Fuertes Ferre G; Caballero Jambrina I; Ruiz Aranjuelo A; Jimeno Sánchez J; Galache Osuna JG; Andrés Esteban EM; Casasnovas Lenguas JA; Diarte de Miguel JA
    Cardiology; 2019; 142(4):203-207. PubMed ID: 31266007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population.
    Hou M; Hyun K; Chew DP; Kritharides L; Amos D; Brieger D
    Heart Lung Circ; 2022 Aug; 31(8):1085-1092. PubMed ID: 35589483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P2Y
    van der Sangen NM; Küçük IT; Ten Berg JM; Beijk MA; Delewi R; den Hartog AW; Appelman Y; Verouden NJ; Kikkert WJ; Henriques JP; Claessen BE
    Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):637-645. PubMed ID: 35916833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prasugrel in the treatment of acute coronary syndrome.
    Spartalis M; Tzatzaki E; Spartalis E; Paschou SA; Athanasiou A; Iliopoulos DC; Siasos G; Voudris V
    Future Cardiol; 2020 Nov; 16(6):559-568. PubMed ID: 32390477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ticagrelor Utilization in Patients With Non-ST Elevation Acute Coronary Syndromes in Romania.
    Cotoban AG; Udroiu CA; Vinereanu D
    Am J Ther; 2021 Apr; 28(3):e271-e283. PubMed ID: 33852478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Ticagrelor and Clopidogrel in Patients With Acute Coronary Syndrome at High Bleeding or Ischemic Risk.
    Akyuz S; Calik AN; Yaylak B; Onuk T; Eren S; Kolak Z; Mollaalioglu F; Durak F; Cetin M; Tanboga IH
    Am J Cardiol; 2024 Jan; 210():241-248. PubMed ID: 37875237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year efficacy and safety of prasugrel and ticagrelor in patients with acute coronary syndromes: Results from a prospective and multicentre ACHILLES registry.
    Ruiz-Nodar JM; Esteve-Pastor MA; Rivera-Caravaca JM; Sandín M; Lozano T; Vicente-Ibarra N; Orenes-Piñero E; Macías MJ; Pernías V; Carrillo L; Candela E; Veliz A; Tello-Montoliu A; Martínez Martínez JG; Marín F
    Br J Clin Pharmacol; 2020 Jun; 86(6):1052-1061. PubMed ID: 31912949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety outcomes of ticagrelor among patients with STE-ACS post streptokinase therapy-a retrospective observational study.
    Ueapornpanith P; Buranakiti B; Chotayaporn T; Phrommintikul A; Yoodee V
    PLoS One; 2023; 18(8):e0289721. PubMed ID: 37540686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety comparing prasugrel/ticagrelor and clopidogrel in Hong Kong post-acute coronary syndrome patients-A 10-year cohort study.
    Lam ASM; Yan BPY; Lee VWY
    Clin Cardiol; 2021 Aug; 44(8):1072-1079. PubMed ID: 34041774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in Treatment Patterns and Incremental Health Care Utilization Due to P2Y12-Associated Complications in Patients with Acute Coronary Syndrome.
    Vyas A; Bash LD; Patel MD; Simpson RJ
    J Manag Care Spec Pharm; 2017 Sep; 23(9):947-956. PubMed ID: 28854078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different P2Y
    Choe JC; Cha KS; Ahn J; Park JS; Lee HW; Oh JH; Choi JH; Lee HC; Hong TJ; Jeong MH;
    Int J Cardiol; 2019 Jan; 274():21-26. PubMed ID: 30224257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-Analysis Comparing P2Y
    Baldetti L; Melillo F; Moroni F; Gallone G; Pagnesi M; Venuti A; Beneduce A; Calvo F; Gramegna M; Godino C; D'Ascenzo F; De Ferrari GM; Capodanno D; Cappelletti AM
    Am J Cardiol; 2020 Jun; 125(12):1815-1822. PubMed ID: 32305225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.
    Abergel E; Nikolsky E
    Vasc Health Risk Manag; 2010 Oct; 6():963-77. PubMed ID: 21057581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching to Clopidogrel in Patients With Acute Coronary Syndrome Managed With Percutaneous Coronary Intervention Initially Treated With Prasugrel or Ticagrelor: Systematic Review and Meta-analysis.
    Hong J; Turgeon RD; Pearson GJ
    Ann Pharmacother; 2019 Oct; 53(10):997-1004. PubMed ID: 30999764
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of P2Y
    Gosling R; Yazdani M; Parviz Y; Hall IR; Grech ED; Gunn JP; Storey RF; Iqbal J
    Platelets; 2017 Dec; 28(8):767-773. PubMed ID: 28267384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical experience with ticagrelor: an Australian and New Zealand perspective.
    Harding SA; Van Gaal WJ; Schrale R; Gunasekara A; Amerena J; Mussap CJ; Aylward PE
    Curr Med Res Opin; 2015 Aug; 31(8):1469-77. PubMed ID: 26086451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Duration and Timing of Initiation of Therapy With Platelet P2Y12 Inhibitors in the Treatment of Patients With Acute Coronary Syndrome].
    SHalaev SV; Safiullina ZM
    Kardiologiia; 2018 Mar; (3):54-62. PubMed ID: 29782272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.